Contineum CEO exercises options, sells 400 shares

Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and related share sale.

Rhea-AI Filing Summary

Contineum Therapeutics CEO Carmine N. Stengone reported an option exercise and related share sale. On February 11, 2026, he exercised 400 stock options at an exercise price of $1.26 per share, receiving 400 shares of Class A common stock.

That same day, he sold 400 Class A common shares at $16.00 per share in an open-market transaction. After these trades, he directly owned 14,954 Class A shares and 128,017 stock options. The filing states these transactions were made under a Rule 10b5-1 trading plan adopted on September 23, 2025, and that the stock options are fully vested and exercisable.

Insider Trade Summary

Exercise and Sale: 400 shares ($6K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Stengone Carmine N.

Role CEO and President

Sold 400 shs ($6K)

Approx. gross sale proceeds $6K

Approx. exercise cost $504.00

Approx. pre-tax spread $6K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	400	$0.00	$0.00
Exercise	Class A Common Stock	400	$1.26	$504.00
Sale	Class A Common Stock	400	$16.00	$6K

Holdings After Transaction: Stock Option (right to buy) — 128,017 contracts (Direct); Class A Common Stock — 14,954 shares (Direct)

Footnotes (3)

1. F1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
2. F2. Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025.
3. F3. The stock options are fully vested and exercisable.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did CTNM CEO Carmine Stengone report on February 11, 2026?

He exercised 400 stock options and sold 400 shares of Class A common stock on February 11, 2026. The exercise price was $1.26 per share and the sale price was $16.00 per share, with both transactions reported as direct holdings.

How many Contineum Therapeutics (CTNM) shares does the CEO own after this Form 4?

After the reported transactions, CEO Carmine Stengone directly owns 14,954 shares of CTNM Class A common stock. He also holds 128,017 stock options, which the filing notes are fully vested and exercisable as of the reported date.

What prices were involved in the CTNM CEO’s option exercise and share sale?

The stock options were exercised at an exercise price of $1.26 per share, converting into 400 Class A shares. Those 400 shares were then sold at $16.00 per share in an open-market transaction reported on the same date.

Was the CTNM CEO’s February 2026 stock sale under a 10b5-1 plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted by CEO Carmine Stengone on September 23, 2025. Such plans pre-schedule trades to help separate them from day-to-day market decisions.

How many CTNM stock options does the CEO retain after exercising 400 options?

Following the exercise of 400 stock options, CEO Carmine Stengone holds 128,017 stock options. The filing explains these options are fully vested and exercisable, meaning he has the right to convert them into Class A common shares.

What roles does Carmine Stengone hold at Contineum Therapeutics (CTNM)?

Carmine N. Stengone is identified as both a director and an officer of Contineum Therapeutics. His officer title is CEO and President, and he filed this Form 4 as a single reporting person with direct ownership of the reported securities.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 04:27 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stengone Carmine N.

(Last) (First) (Middle)

3565 GENERAL ATOMICS COURT, SUITE 200

(Street)

SAN DIEGO CA 92121

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Contineum Therapeutics, Inc. [ CTNM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO and President

3. Date of Earliest Transaction (Month/Day/Year)
02/11/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Common Stock	02/11/2026		M(1)		400	A	$1.26	15,354(2)	D
Class A Common Stock	02/11/2026		S(1)		400	D	$16	14,954	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.26	02/11/2026		M(1)			400	(3)	11/13/2028	Class A Common Stock	400	$0	128,017	D

Explanation of Responses:

1. These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.

2. Includes 1,246 shares purchased through Issuer's Employee Stock Purchase Plan on November 15, 2024 and 2,096 shares purchased through Issuer's Employee Stock Purchase Plan on May 15, 2025.

3. The stock options are fully vested and exercisable.

	/s/ Peter Slover, Attorney-in-Fact	02/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.